natgillin/translations-raw huggingface dataset:
about 10-200 mg/ml of one or more pharmaceutically acceptable excipients effective to form a lyophilized cake; a pharmaceutically effective amount of succinate effective to provide a pharmaceutically acceptable pH. 
Smjesa prema bilo kojem od prethodnih zahtjeva, naznačeno time da ista obuhvaća: a) farmaceutski djelotvornu količinu acetatne soli kaspofungina; b) oko 10-200 mg/ml jedne ili više farmaceutski prihvatljive pomoćne tvari djelotvorne za tvorbu liofilizirane kolača; c) farmaceutski djelotvorna količina sukcinata djelotvorna za osiguranje farmaceutski prihvatljive PH vrijednosti.
The system of any one of claims 1 to 3 wherein the system is configured such that the primary drive signal and the secondary drive signal overlap. 
Sustav u skladu sa zahtjevom 1, naznačen time, da su upravljačka sredstva nadalje podešena da prenose upravljački signal tako da se prva frekvencija i druga frekvencija preklapaju.
A humanized CD37-specific immunoglobulin binding protein comprising: 
Humanizirani CD37-specifični vezni protein obuhvaća:
The device according to one of Claims 1 to 6, characterized in that the sealing member (114) is a sealing member in the form of a hollow profile or tube, the cavity (172) of which contains a fluid or gas which a compressor (146) may selectively pressurize. 
Uređaj u skladu s jednim od patentnih zahtjeva 1 do 5, naznačen time, da je element za brtvljenje (114) element u obliku šupljeg profila ili cijevi, čija šupljina (172) sadržava tekućinu ili plin koji kompresor (146) može selektivno stlačiti.
The method according to any of claims 5-8, wherein said rinsing cartridge is detachably installed onto said pressure chamber, or alternatively said rinsing cartridge constitutes a separate rinsing unit. 
Metoda u skladu sa bilo kojim od patentnih zahtjeva 4-7, gdje je navedeni spremnik za pranje (20, 118, 132) odvojivo instaliran na navedenu komoru za pritisak (10), ili alternativno navedeni spremnik za pranje (20,118,132) predstavlja odvojenu jedinicu za pranje.
The method according to any one of the preceding claims further including an additional step where wet solids are treated with a heatable roll grinder to reduce particle size and begin pre-drying. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno uključuje dodatni korak u kojem se mokru čvrsta tvar obradi valjkastim mlinom koji se može grijati kako bi se smanjila veličinu čestica i započelo s predsušenjem.
The maleate salt of claim 2, wherein at least 90% by weight of the maleate salt is single crystalline form A, and the X-ray powder diffraction pattern of the single crystalline form A is shown in FIG. 11 . 
Fumarat sol sukladno bilo kojem od patentnih zahtjeva 1-3, pri čemu je najmanje 90% težine fumarat soli jedan kristalni oblik A, naznačen time što obrazac rendgenske difrakcije na prahu (XRPD) ima vršne vrijednosti na:
Compound for use according to claim 5 wherein the tumors are selected from the group consisting of oesophagus, stomach, pancreas, colon, prostate, breast, uterus and uterus appendage, kidneys and lung tumours. 
Spoj za uporabu prema zahtjevu 5 gdje se tumori izabiru iz grupe koja obuhvaća tumor jednjaka, želuca, gušterače, kolona, prostate, dojke, maternice i priraslica maternici, bubrega 1 pluća,
Concerning the properties of said veneer according to the invention, also reference is made to the hitherto description, and it is explicitly made reference thereto., The process according to the invention, the block of wood being obtained according to the invention, and the veneer being obtained according to the invention have a series of particular advantages. For the solution according to the invention, the initially described procedure according to the prior art is inverted so that the veneer surface to be manufactured is already defined prior to the cutting/slicing, and is only subsequently cut/sliced. 
Å to se tiče svojstava navedenog furnira koji je u skladu s ovim izumom, također se poziva na opis koji se nalazi ovdje i izričito se poziva na njega. Postupak koji je u skladu s ovim izumom i furnir koji je dobiven u skladu s ovim izumom imaju niz posebnih prednosti. Za rješenje koje je u skladu s ovim izumom, postupak koji je u skladu sa stanjem tehnike i koji je na početku opisan promijenjen je u tome, daje površina furnira koji se treba proizvesti određena već prije rezanja/rezanja na kriške i samo je nakon toga obavljeno rezanje/rezanje na kriške.
The use as claimed in claim 9, wherein the crops are crops of wheat, barley, rye, triticale, durum, rice, corn, sugarcane, sorghum, soybean, pulse crops, peanut, sunflower, sugarbeet, potato, cotton, brassica crops, turf, grapes, pomefruit, stonefruit, citrus, coffee, pistachio, garden ornamentals, bulb ornamentals, conifers and deciduous trees. 
Primjena u skladu sa zahtjevom 6, naznačena time što su usjevske biljke usjevi pšenice, ječma, raži, tritikale pšenice, durum pšenice, riže, kukuruza, šećerne trske, siraka, soje, mahunarki, kikirikija, suncokreta, šećerne repe, krumpira, pamuka, kupusnjača, travnatih terena, grožđa, jabučastih biljaka, koštuničavih biljaka, citrusa, kave, pistacio, vrtnih biljaka, lukovica, četinarskog 1 listopadnog drveća.
The residue was chromatographed with 10:10:1 EtOAc/Hexane/Et3N to give 1g as a yellow oil (3.0 g, 4.65 mmol). 
Ostatak se kromatografira 10:10:1 smjesom FtOAc/heksan/E&GN kako bi se dobilo 1g u obliku žutog ulja (3,0 g, 4,65 mmol).
The method according to claim 1, wherein said intervertebral disc-related pain is selected from neck pain, chronic neck pain, low back pain, and chronic low back pain. The method according to claim 1, wherein said intervertebral disc-related pain is coccygodynia. 
Kompozicija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačena time što je navedena bol povezana s intervertebralnim diskom odabrana od boli u vratu, kronične boli u vratu, boli u donjem dijelu leđa i kronične boli u donjem dijelu leđa.
The aqueous pharmaceutical suspension according to claim 89, further comprising, by weight/volume-(g/100 mL); about 0.1% of titanium dioxide. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 89, naznačena time što dodatno sadrži, težinski/volumno (g/100 ml), otprilike 0,1 % titanijevog dioksida.
Said pins are preferably provided on the inner part at a location adjacent to said indentations of the first and second part (when these parts are attached to the inner part). 
Poželjno je da su navedeni klinovi predviđeni na unutarnjoj strani na mjestima koja su u blizini navedenih nazubljenja prvog i drugog dijela (kada su ovi dijelovi spojeni s unutarnjim dijelom).
A disadvantage with using these bolts as suspension devices is that they, together with the special suspension coupling, protrude substantially from the roof of the tunnel, and must therefore be cut and/or covered by a thick layer of rendering concrete. 
Nedostatak kod korištenja ovih sidara kao naprava za ovješanje je taj, da ona sa posebnim ovjesnim spojnicama u biti strše iz svoda tuncla i zbog toga ih se mora odrezati i/ili pokriti debelim slojem obložnog betona.
The lipid of claim 1, wherein at least one of the alkyl chains has a double bond, preferably wherein at least one of the alkyl chains has a cis double bond. 
Lipid skladu s patentnim zahtjevom 1, naznačen time, da najmanje jedan od R1, R2 i R3 ima dvostruku vezu, poželjno cis dvostruku vezu.
The oligonucleotide decoy of claim 1, comprising a sequence that is at least 90% identical with SEQ ID NO:33. 
Oligonukleotidna zamka, naznačena time, da se sastoji od sekvence od SEQ ID NO:41.
The method according to claim 17, wherein moving the plant along the cutting devices comprises rotating the plant simultaneously to pulling the plant toward the user. 
Postupak prema patentnom zahtjevu 12, naznačen time što se pomicanje biljke duž reznih uređaja sastoji od zakretanja biljke istodobno s povlačenjem biljke prema korisniku.
The coupling reaction is suitably performed at -25°C to 150°C, conveniently at ambient temperature. 
Reakcija spajanja se prikladno provodi pri -25 *C do 150 "C, poželjno pri sobnoj temperaturi.
and R4, taken together with the adjacent nitrogen atom, form an azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl, the piperydinyl ring being optionally substituted with one or two (C1-C2)alkyl group(s) and the piperazinyl ring being optionally substituted on the other N-atom with a (C1-C4)alkyl, benzyl, or phenylsulfonyl group; or a pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl ring fused with a benzene ring; 
R> i R", uzeti zajedno sa susjednim dušikovim atomom tvore azetidinilni, pirolidinilni, morfolinilni, piperidinilni ili piperazinilni prsten, a piperidinilni prsten može biti supstituiran s jednom ili dvjema (C;-C>)alkilnim skupinama te piperazinilni prsten može biti supstituiran na drugom N-atomu s (C,-Cg)alkilnom, benzilnom ili fenilsulfonilnom skupinom; ili pirolidinilni, piperidinilni, morfolinilni ili piperazinilni prsten fuzioniran s benzenskim prstenom;
is a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-8 cycloalkyl group, an optionally substituted aryl group, an optionally substituted ar-C1-6 alkyl group or an optionally substituted acyl group). The compound or the salt thereof according to any one of claims 1 to 10, wherein G1 and G2 are CH; G3 is a nitrogen atom; and R4 is a group as represented by a general formula (5-1a): (wherein R86 is an optionally substituted C1-6 alkyl group, an optionally substituted C3-8 cycloalkyl group, an optionally substituted C3-8 cycloalkyl-C1-6 alkyl group, an optionally substituted aryl group or an optionally substituted ar-C1-6 alkyl group). 
je atom vodika, po izboru zaštićena karboksilna skupina, po izboru supstituirana karbamoilna skupina, po izboru supstituirana C1-6 alkilna skupina ili po izboru supstituirana arilna skupina; i R11 je atom vodika, po izboru supstituirana C1-6 alkilna skupina, po izboru supstituirana C3-8 cikloalkilna skupina, po izboru supstituirana arilna skupina, po izboru supstituirana ar-C1-6 alkilna skupina ili po izboru supstituirana acilna skupina), pri čemu su ar-C1-6 alkilna skupina i karboksilna zaštitna skupina kao što je gore definirano.
A fiber cement product obtained according to any one of the preceding claims. 
Vlaknasti cementni proizvod, naznačen time što sadrži najmanje jednu profiliranu površinu dobivenu prema bilo kojem od prethodnih patentnih zahtjeva.
The antisense oligonucleotide of any one of clauses 15-17, wherein the oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide. 
Antisens oligonukleotid u skladu sa zahtjevom 15, naznačen time što navedeni antisens oligonukleotid je kemijski vezan na jedan ili više ostataka ili konjugata koji poboljšavaju aktivnost, raspodjela po stanici, ili unos u stanicu antisens oligonukleotida.
The most common adverse health effects of sugar are tooth decay and obesity. 
Najčešći neželjeni učinci na zdravlje su kvarenje zuba i pretilost.
Process according to claim 2, wherein the liquid pharmaceutical formulation is prepared from ingredients including chelate powder, water and meglumine, and wherein the amount of calcium in the ingredients used to prepare the final liquid pharmaceutical formulation is less than 50 ppm. 
PPI i time da je količina kalcija u sastojcima koji se koriste za farmaceutsku otopinu, odnosno u kelatnom prahu, naročito DOTA, vodi i megluminu, manja od 50 ppm, poželjno manja od 20 ppm.
A product comprising (a) a PDE4 inhibitor as defined in any one of claims 1 and 3 to 6 and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease which responds to M3 antagonism. 
Proizvedeni lijek, naznačen time, da sadrži (a) inhibitor PDE4 kako se definira u bilo kojem od patentnih zahtjeva 113 do 6 i (b) antagonist muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2, u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u liječenju bolesnika koji boluje od ili je osjetljiv na bolest dišnih putova koja reagira na M3 antagonizam.
The starting concentration of SDS in a sample will generally be known, because SDS is not naturally present in cells and the quantity of SDS that was added during processing of cell-derived material will have been monitored. 
Početna koncentracija SDS u uzorku će općenito biti poznata, budući da SDS nije prirodno prisutan u stanicama, a količina SDS koja se dodala za vrijeme obrade materijala izvedenog iz stanice će se pratiti.
A combination according to claim 1 or 2 characterised in that the active ingredients (a) and (b) form part of a single pharmaceutical composition. 
Kombinacija sukladno patentnom zahtjevu 9, naznačena time, da je djelatni spoj (c) odabran iz skupine koja se sastoji od (a) inhibitora PDE IV i (b) kortikosteroida.
is hydrogen, C1 to C6 alkyl, phenyl unsubstituted or substituted by C1 to C6 alkyl, or COR6 acyl group (R6 being hydrogen; C1 to C6 straight chain or branched alkyl; phenyl or benzoyl respectively unsubstituted or substituted by C1 to C6 alkyl); and salts thereof; for use in the prophylaxis and/or the treatment selected from: 
Ru je vodik, C, do Cg alkil, fenil nesupstituiran ili supstituiran s C, do Cg alkilom, COR; acilnom skupinom (Rs je vodik; C; do Cg ravnolančani ili razgranati alkil; odnosno fenil ili benzoil nesupstituiran ili supstituiran s C, do Cy alkilom), ili bilo kojom skupinom koja vodi do hidroksila nakon biološke razgradnje ili kemijskog uklanjanja zaštite; i njegove soli; za uporabu u prevenciji 1/ili liječenju karcinoma prostate.
The residue was concentrated in vacuo and purified on the chromatotron using a 2000-micron rotor (SiO2) and 5% ethyl acetate-20% ethyl acetate-hexanes as the eluant to give the desired product (52 mg). 
Ostatak se koncentrira in vacuo i pročisti na kromatotronu uporabom 2000-mikronskog rotora (SiO») i 5% etil acetat-20% etil acetat-heksana kao sredstva za eluaciju da bi se dobio željeni produkt (52 mg).
A lateral pipe adaptor as claimed in claim 11 or claim 12 wherein the one or more shims have a ridge provided upon the surface of their inner end. 
Adapter za bočne cijevi (1) u skladu s patentnim zahtjevom 10 ili patentnim zahtjevom 11, naznačen time što jedna ili više podložnih pločica (50) imaju greben načinjen na površini svojeg unutarnjeg kraja (52).
The process of claim 23, wherein said crystalline trans-(±)-±9-tetrahydrocannabinol comprises at least 95%, preferably at least 98%, more preferably at least 99%, even more preferably at least 99.5% and most preferably at least 99.9% by weight of the total amount of cannabinoids in said dosage form. 
Postupak prema zahtjevu 23, naznačen time da navedeni kristalni trans-(±)-A9-tetrahidrokanabinol sadrži barem 95%, poželjno barem 98%, poželjnije barem 99%, još poželjnije barem 99.5% i najpoželjnije barem 99.9% težine ukupne količine kanabinoida u navedenom obliku doziranja.
a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. 
njegov stereoizomer, enantiomer ili tautomer, njegova farmaceutski prihvatljiva sol, ili njegov farmaceutski sastav.
The organic layer was washed with brine, dried over Na2SO4 and concentrated. 
Organski sloj ispere se slanom vodom, osuši preko Na»SOx, te koncentrira.
The invention also relates to an assembly of a casting plate and a device for holding and replacing casting plates wherein the casting plate comprises at least one protrusion or protuberance for interacting with a plate passage detector of a device as described above. 
Sklop ploče za lijevanje (194, 20a) 1 uređaja za držanje i zamjenu ploče za lijevanje (194, 203) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da ploče za lijevanje (19a, 20a), sadrži najmanje jednu izbočinu
and wherein the composition has a pH of from about 5 to about 6. 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 6, gdje farmaceutska kompozicija ima pH od oko 4.
The neurovascular mechanism of clitoral erection: nitric oxide and cGMP-stimulated activation of BKCa channels. FASEB J. 2004 Sep;18(12):1382-91 . Use of a combination of testosterone or an analogue thereof and tadalafil, in the preparation of a medicament for the treatment of female sexual dysfunction, wherein said testosterone or an analogue thereof and tadalafil are released at essentially the same time. 
Kombinacija testosterona ili njegovog analoga koji ima istu vrstu aktivnosti i tadalafila, za uporabu u liječenju ženske seksualne disfunkcije, naznačena time što se tadalafil oslobađa u isto vrijeme kao i navedeni testosteron ili njegov analog, i gdje su navedeni testosteron ili njegov analog pruženi u vidu sublingvalne, buko-mukozne ili intranazalne formulacije tako da se pik nivoa testosterona u serumu dobiva 1-20 minuta nakon primjene, pa se pikovi efekata testosterona ili njegovog analoga i tadalafila preklapaju.
the transformation of the diol of formula XX wherein n is as above into the alcohol ester of formula XXI wherein n is as above and R5 is an ester protecting group; 
E gdje je n kao što je gore opisan i R? je esterska zaštitna skupina; bl) spajanje alkoholnog estera formule XXI s tetrahidropiranskim derivatom formule XXII
A composition comprising: a chimeric Cas9 protein, or a polynucleotide encoding said chimeric Cas9 protein, wherein the chimeric Cas9 protein comprises a modified Cas9 protein having reduced nuclease activity compared to the corresponding wild-type Cas9, and comprises a heterologous polypeptide that: 
(a) kimerni protein Cas9, ili polinukleotid koji kodira navedeni kimerni protein Cas9, pri čemu kimerni protein Cas9 obuhvaća modificirani protein Cas9 koji ima smanjeno djelovanje nukleaze u usporedbi s odgovarajućim divljim tipom Cas9; te obuhvaća heterologni polipeptid koji: i
X and Y are each independently selected from the group consisting of Br, Cl and —CH3; 
Xi Y su svaki neovisno odabrani iz skupine koja se sastoji od Br, Cli -CH;;
A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or diluent. A method for treating cancer, wherein the cancer is pancreatic cancer, prostate cancer, lung cancer, melanoma, breast cancer, colon cancer, or ovarian cancer the method comprising: administering to a subject in need thereof an effective amount of the compound of claim 2 . The compound of claim 10, wherein n is 0, 1, or 2. 
7. = Farmaceutski pripravak, naznačen time, da sadrži spoj sukladno bilo kojem od prethodnih zahtjeva i farmaceutski prihvatljivi nosač ili otapalo. 8. - Spoj sukladno bilo kojem od zahtjeva 1 do 6 ili farmaceutski pripravak sukladno zahtjevu 7, naznačeni time, da su za liječenje raka kod čovjeka. Spoj ili farmaceutski pripravak za primjenu sukladno zahtjevu 8,, naznačen time, da je rak rak pankreasa, rak prostate, rak pluća, melanom, rak dojke, rak debelog crijeva, ili karcinom jajnika.
The method of claim 15, wherein the vaccine is administered subcutaneously. The method of claim 1, wherein the vaccine is administered intravenously, intradermally, subcutaneously, intramuscularly, orally, transdermally, intranasally, interperitoneally, transmucosally or rectally. 
Pripravak cjepiva za uporabu prema zahtjevu 10, naznačen time da se pripravak cjepiva primjenjuje intravenozno, intradermalno, potkožno, intramuskularno, oralno, transdermalno, intranazalno, interperitonealno, transmukozno ili rektalno.
The term lower means having 1 to 6 carbon atoms in the case of an alkyl or an alkoxy group and having 2 to 6 carbon atoms in the case of an alkenyl group. 
Odrednica niži označava skupinu s 1 do 6 atoma ugljika u slučaju alkilne ili alkoksi skupine te skupinu s 2 do 6 atoma ugljika u slučaju alkenilno skupine.
Preferably, the curing is conducted at atmospheric pressure. In certain embodiments the composition is shaped in step b) to form an extended release matrix formulation in the form of tablet. 
Postupak prema zahtjevu 1, 2 ili 3, naznačen time da je u koraku b) sastav oblikovan da formira formulaciju matrice s produljenim otpuštanjem u obliku tablete.
a light chain CDR1 sequence comprising the amino acid sequence of SEQ ID NO:13; 
CDRI1 slijed lakog lanca koji sadrži aminokiselinski slijed SEQ ID NO:13; di.
A composition comprising desmopressin for use in the treatment of nocturia or nocturnal polyuria by reducing nocturnal voids and/or by reducing nocturnal urine volume and/or by increasing an initial period of undisturbed sleep in a female patient in need thereof, the composition comprising an orodispersible dose of 25 microgram of desmopressin, wherein the dose is measured as the free base of desmopressin, wherein the dose is taken 0.8 to 3 hours prior to the patient's bedtime. 
Pripravak koji sadrži dezmopresin za uporabu u liječenju nokturije ili noćne poliurije za povećanje početnog razdoblja nesmetanog spavanja kod ženskog pacijenta kojem je potreban, naznačen time da pripravak sadrži orodisperzibilnu dozu od 25 mikrograma dezmopresina pri čemu se doza mjeri kao slobodna baza dezmopresina i koja se daje pacijentu prije spavanja.
This is a major advantage during operation, as an endoscopic operation requires movement and rotation of one or more of the instruments positioned inside the body during the operation, and which can be complicated to control. 
To je važna prednost za vrijeme rada, budući da endoskopska operacija zahtjeva pomicanje 1 rotiranje jednog instrumenta ili više instrumenata koji su smješteni unutar tijela za vrijeme operacije, i čije upravljanje je vrlo komplicirano.
The method of any one of claims 6, 7, and 8, wherein: 
Metoda iz bilo kojeg zahtjeva 6,7 i 8, pri čemu:
A compound according to any one of Claims 1 to 8 wherein R3 is fluoro, hydroxymethyl, methoxymethyl, or cyanomethyl; or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s bilo koji od patentnih zahtjeva 1 do 8, naznačen time što R3 je fluor, hidroksimetil, metoksimetil ili cijanometil; ili njegova farmaceulski prihvatljiva sol.
There is also provided a process for preparing such a pharmaceutical formulation which comprises mixing the ingredients. 
Također se osigurava postupak priprave takve farmaceutske formulacije, koji se sastoji u miješanju sastojaka.
The method according to claim 1, wherein following addition of AMP to the suspension, the suspension is passed through a passage having a suspension throughput regulated as a function of the suspension conductivity. 
Uporaba prema zahtjevu 16, naznačena time da nakon dodavanja navedenog AMP u navedenu suspenziju, suspenzija prolazi kroz prolaz koji ima protok suspenzije koji je reguliran kao funkcija vodljivosti suspenzije.
Additionally, elimination of a hundred gallon tank or water container eliminates a safety issue because such a tank adds a significant amount of weight to a vehicle and could create tipping problems. 
Uz to, odbacivanje spremnika od nekoliko stotina litara volumena ili cisterne za vodu otklanja jedan problem sigurnosti, budući da takav spremnik dodaje značajnu količinu težine vozilu i može stvarati probleme zbog mogućeg prevrtanja. f.